RNA polymerase variant, preparation method thereof and application of RNA polymerase variant in RNA synthesis

CN118922535AActive Publication Date: 2024-11-08NANJING VAZYME BIOTECH CO LTD

Patent Information

Application Number
CN202480001786.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-01
Filing Date
2024-03-01
Publication Date
2024-11-08
Estimated Expiration
2044-03-01

AI Technical Summary

Technical Problem

In the production process of RNA vaccines, the presence of double-stranded RNA impurities can cause strong immunogenicity. It is difficult to effectively reduce their production and residual amounts with existing technology, affecting the quality and safety of RNA synthesis.

Method used

Develop an RNA polymerase variant whose amino acid sequence is modified through specific mutation sites (such as D130, N171, K172, R173, Y178, R298, Y385, K387, D388 or F880) to improve its performance in RNA synthesis. catalytic efficiency and product integrity, and reduces the generation of double-stranded RNA impurities in in vitro transcription systems through contact with DNA templates.

Benefits of technology

Effectively reduces the generation of double-stranded RNA impurities during in vitro transcription, improves the integrity and capping rate of RNA products, significantly reduces the residual amount of double-stranded RNA contaminants, improves the quality of mRNA and saRNA, and reduces the amount of double-stranded RNA produced by double-stranded RNA. Immunogenicity risk caused by impurities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000023_0000
    Figure 00000023_0000
Patent Text Reader

Abstract

According to the RNA polymerase variant and the preparation method thereof, the RNA polymerase variant is applied to in-vitro transcription, an RNA product with low dsRNA pollution and high integrity can be obtained, meanwhile, the utilization efficiency of cap analogues in a co-transcription capping reaction system can be improved, and cost is saved. In addition, the invention further provides a method for generating RNA through in-vitro transcription.
Need to check novelty before this filing date? Find Prior Art

Description

RNA polymerase variants, preparation methods thereof, and applications thereof in RNA synthesis Technical Field

[0001] The present application belongs to the field of biotechnology, and specifically relates to RNA polymerase variants, preparation methods thereof, and applications thereof in RNA synthesis. Background Art

[0002] At the end of 2019, the novel coronavirus disease (COVID-19) broke out globally, infecting billions of people worldwide. Before the release of Paxlovid (a combination of namatevir and ritonavir tablets) (which received emergency approval from the FDA on November 22, 2021), vaccines became the most effective line of defense against infection. In this massive global battle against the pandemic, billions of people received COVID-19 vaccines, including BNT162b2 (mRNA vaccine) developed by BioNTech and Pfizer, mRNA-1273 (mRNA vaccine) developed by Moderna, and AZD1222 (adenovirus vector vaccine) developed by AstraZeneca. RNA vaccines have shown the highest protective efficacy. By preventing infection, reducing the incidence of severe illness, and curbing the spread of the epidemic, mRNA vaccines have made a significant contribution to the fight against the pandemic.

[0003] The research and development cycle of mRNA vaccines is relatively short, and new vaccine candidates can be quickly developed to respond to viral mutations. Through the dual mechanisms of humoral immunity and T cell immunity, it has strong immunogenicity and significant effects. The production process is simple, making it easy to develop and mass-produce efficiently, allowing for rapid global supply in the fight against epidemics similar to the new coronavirus.

[0004] According to the latest news, in addition to mRNA, research on circular RNA (circRNA)-related drugs has also made breakthroughs. Orna Therapeutics has developed an in vivo cell therapy product using circRNA. In a research report released at the 2022 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, it has demonstrated its huge application potential in other fields such as cancer treatment.

[0005] RNA has made great progress in the development of vaccines and other drugs. However, the removal of some impurities in the actual production process requires further study. Double-stranded RNA (dsRNA) impurities can cause strong immunogenicity (Goubau et al., 2014; Kato et al., 2006; Mu et al., 2018). Therefore, it is urgent to develop methods to effectively reduce double-stranded RNA impurities.

[0006] Summary of the Invention

[0007] The present application provides an RNA polymerase variant, a method for preparing the same, and its use in RNA synthesis. In a first aspect of the application, the present application provides an RNA polymerase variant, whose amino acid sequence, relative to SEQ ID NO: 1, comprises at least one, at least two, at least three, at least four, at least five, or at least six amino acid mutations at positions selected from D130, N171, K172, R173, Y178, R298, Y385, K387, D388, or F880, wherein the type of the mutation is selected from deletion or substitution, and the amino acid sequence of the variant has at least 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 1. In some embodiments, the variant comprises one, two, three, four, five, or six amino acid mutations at positions selected from D130, N171, K172, R173, Y178, R298, Y385, K387, D388, or F880; wherein the type of the mutation is selected from deletion or substitution. In some embodiments, the mutation type is deletion (denoted by DEL, for example, DEL5, indicating a deletion of an amino acid at the 5th position). In some embodiments, the mutation type is substitution (for example, K5A, indicating a mutation of lysine at the 5th position to alanine). In some embodiments, the mutation type includes deletion and substitution, i.e., deletion occurs at some positions and substitution occurs at some positions.

[0008] In some embodiments, the RNA polymerase variant provided herein has an amino acid mutation relative to SEQ ID NO: 1, wherein the mutated amino acid position is selected from N171, K172, R173, Y178, R298, Y385, K387, D388, or F880, and the mutation type is a substitution or deletion. In some embodiments, the amino acid sequence of the variant has an amino acid mutation relative to SEQ ID NO: 1, wherein the mutation is selected from:

[0009] (1) a substitution at position N171, wherein the substituted amino acid is G; or

[0010] (2) a substitution or deletion at position K172, wherein the substituted amino acid can be selected from A, G, E, D, H, Y, S, W, P, I, M, V, F, T, C, N, or L; or

[0011] (3) a substitution or deletion at position R173, wherein the substituted amino acid can be selected from A, C, G, E, D, H, Y, S, W, P, N, Q; or

[0012] (4) a substitution at position Y178, wherein the substituted amino acid is H; or

[0013] (5) a substitution at position R298, wherein the substituted amino acid is A; or

[0014] (6) a substitution at position Y385, wherein the substituted amino acid can be selected from A, E, or D; or

[0015] (7) a substitution at position K387, wherein the substituted amino acid can be selected from A, Y, S, or Q; or

[0016] (8) a substitution at position D388, wherein the substituted amino acid is selected from A, G, and L; or

[0017] (9) Substitution at position F880, wherein the substituted amino acid can be selected from A, G, and W.

[0018] In some embodiments, the RNA polymerase variant provided herein comprises, relative to SEQ ID NO: 1, a mutation in two, three, four or five amino acids at positions selected from D130, K172, R173, Y178, R298, Y385, K387, D388 or F880, and the amino acid sequence of the variant has at least 95%, 96%, 97%, 98%, 99% or 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the variant comprises: (1) a mutation at the K172 position, and further comprises a mutation of one, two, three or four amino acids at a position selected from D130, R173, Y178, R298, Y385, K387, D388 or F880, wherein the mutation type is substitution or deletion; or (2) a mutation at the R173 position, and further comprises a mutation of one, two or three amino acids at a position selected from D130, Y178, R298, K387 or D388, wherein the mutation type is substitution or deletion; or (3) a mutation of two or three amino acids at a position of R298, Y385, K387 or D388, wherein the mutation type is substitution or deletion. In some embodiments, the amino acid sequence of the variant is the same as that of SEQ ID NO: 1. NO: 1, having any combination of mutation points selected from the following: K172+R173, D130+K172, K172+K387, K172+F880, K172+D388, K172+R298, D130+R173, R173+Y178, R173+D388, R173+R298, K387+R298, Y385+ R298, D388+R298, Y385+K387, Y385+D388, K387+D388, K172+R173+Y385, K172+R1 73+D388, K172+R173+K387, K172+R173+F880, K172+R173+Y178, D130+K172+R173, D130+K172+Y178, D130+K172+K387, D130+R173+D388, K172+Y178+D388, D130+K1 72+D388, K172+K387+R298, Y385+K387+D388, K172+R173+Y385+F880, K172+R173+ D388+F880, K172+R173+Y178+D388, D130+K172+R173+D388, D130+K172+R173+Y1 78. D130+R173+Y178+K387, D130+K172+Y178+D388, D130+K172+R173+Y178+D388.In some embodiments, further, the variant has a mutation type at position D130 of D130E. In some embodiments, further, the variant has a mutation type at position K172 of DEL172, K172A, or K172G. In some embodiments, further, the variant has a mutation type at position R173 of DEL173, R173A, R173G, or R173C. In some embodiments, further, the variant has a mutation type at position Y178 of Y178H or Y178P. In some embodiments, further, the variant has a mutation type at position R298 of R298A. In some embodiments, further, the variant has a mutation type at position Y385 of Y385A. In some embodiments, further, the variant has a mutation type at position K387 of K387S, K387Y, or K387G. In some embodiments, further, the mutation type of the variant at position D388 can be selected from D388Y, D388A or D388G. In some embodiments, further, the mutation type of the variant at position F880 can be selected from F880A or F880Y.

[0019] In some embodiments, the variant comprises a mutation at position K172 and further comprises a mutation of one, two, three or four amino acids at positions selected from D130, R173, Y178, R298, Y385, K387, D388 or F880, wherein the mutation type is substitution or deletion, and the amino acid sequence of the variant has at least 95%, 96%, 97%, 98%, 99% or 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the variant comprises a mutation group selected from any one of the following: K172+R173, D130+K172, K172+K387, K172+F880, K172+D388, K172+R298, K172+R173+Y385, K172+R173+D388, K172+R173+K387, K172+R173+F880, K172+R173+Y178, D130+K172+R173, D130+K172+Y178, D130+K172+R173 In some embodiments, further, the variant has a mutation type of D130E at position D130. In some embodiments, further, the variant has a mutation type at K172 selected from DEL172, K172A, or K172G. In some embodiments, further, the variant has a mutation type at R173 selected from DEL173, R173A, R173G, or R173C. In some embodiments, further, the variant has a mutation type at Y178 selected from Y178H. Further, the variant has a mutation type at R298 selected from R298A. In some embodiments, further, the variant has a mutation type at Y385 selected from Y385A. In some embodiments, further, the variant has a mutation type at K387 selected from K387S, K387Y, or K387G. In some embodiments, further, the variant has a mutation type at D388 selected from D388Y, D388A, or D388G. In some embodiments, further, the mutation type of the variant at position F880 can be selected from F880A or F880Y.

[0020] In some embodiments, the variant comprises a mutation at position R173 and further comprises a mutation of one, two or three amino acids selected from positions D130, Y178, R298, K387, D388 or F880, wherein the mutation type is a substitution or deletion, and the amino acid sequence of the variant has at least 95%, 96%, 97%, 98%, 99% or 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the variant comprises a mutation group selected from any one of the following: D130+R173, R173+Y178, R173+D388, R173+R298, D130+R173+D388, D130+R173+Y178+K387. In some embodiments, further, the variant has a mutation type at position D130 of D130E. In some embodiments, further, the variant has a mutation type at position R173 selected from DEL173, R173A, R173G, or R173C. In some embodiments, further, the variant has a mutation type at position Y178 selected from Y178H or Y178P. In some embodiments, further, the variant has a mutation type at position R298 selected from R298A. In some embodiments, further, the variant has a mutation type at position K387 selected from K387Y. In some embodiments, further, the variant has a mutation type at position D388 selected from D388Y or D388G.

[0021] In some embodiments, the variant comprises a mutation in any two or three amino acids selected from the group consisting of R298, Y385, K387, or D388, wherein the mutation type is a substitution or deletion, and the amino acid sequence of the variant has at least 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to SEQ ID NO: 1. In some embodiments, the variant comprises a mutation group selected from any one of the following: K387+R298, Y385+R298, D388+R298, Y385+K387, Y385+D388, K387+D388, or Y385+K387+D388. In some embodiments, further, the mutation type at the R298 position of the variant is R298A. In some embodiments, further, the substitution at the Y385 position of the variant is Y385A. In some embodiments, further, the substitution at position K387 of the variant may be selected from K387S or K387Y. In some embodiments, further, the substitution at position D388 of the variant may be selected from D388A or D388G.

[0022] In some embodiments, the amino acid sequence of the variant described herein has at least 99.0%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or higher sequence identity to any one of the amino acid sequences selected from SEQ ID NOs: 2-141. In some embodiments, the amino acid sequence of the variant described herein is selected from SEQ ID NOs: 2-141.

[0023] In a second aspect, the present application provides a method for preparing an RNA polymerase variant, comprising producing at least one RNA polymerase variant described herein in a host cell. In some embodiments, the host cell contains an expression vector carrying a nucleotide sequence corresponding to the RNA polymerase variant described herein. In some embodiments, various modifications may be present in the coding region of the polynucleotide sequence, as long as the amino acid sequence of the variant does not change due to codon degeneracy or the preferred codons in the organism in which the variant is expressed. In some embodiments, the nucleotide sequence is selected from SEQ ID NOs: 143-282.

[0024] In a third aspect, the present application provides a method for reducing the generation of dsRNA impurities during in vitro transcription to prepare RNA, comprising contacting a DNA template with one or more RNA polymerase variants described herein and incubating them in an in vitro transcription system.

[0025] In a fourth aspect, the present application provides a method for improving the integrity of in vitro transcribed RNA products, comprising contacting a DNA template with one or more RNA polymerase variants described in the present application and incubating in an in vitro transcription system.

[0026] In a fifth aspect, the present application provides a method for generating RNA, comprising contacting a DNA template with one or more RNA polymerase variants described in the present application under conditions that result in the generation of RNA transcription products, and incubating in an in vitro transcription system.

[0027] In some embodiments, the RNA prepared using the methods described herein can be coding RNA or non-coding RNA, including but not limited to mRNA, siRNA, gRNA, saRNA, dsRNA, ssRNA, miRNA, piRNA, shRNA, etc. In some embodiments, the RNA product is mRNA. In some embodiments, the RNA product is saRNA.

[0028] In some embodiments, the DNA template length can be selected from 1000-13000 bp. In some embodiments, the DNA template length can be selected from 8000-13000 bp. In some embodiments, the DNA template length can be selected from 10000-13000 bp.

[0029] In some embodiments, the amount of residual dsRNA impurities in RNA produced using the methods described herein after purification is reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more compared to a wild-type RNA polymerase (SEQ ID NO: 1). In some embodiments, the amount of residual dsRNA impurities in RNA produced using the methods described herein after purification (residual dsRNA / total RNA) is less than 0.04%, less than 0.03%, less than 0.02%, less than 0.01%, less than 0.005%, less than 0.004%, less than 0.003%, less than 0.002%, less than 0.001%, less than 0.0005%, less than 0.0003%, or less than 0.0001%.

[0030] In some embodiments, the integrity of the purified mRNA produced using the methods described herein is improved by at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% compared to that produced using wild-type T7 RNA polymerase (SEQ ID NO: 1).

[0031] In some embodiments, the integrity of the saRNA product produced using the methods described herein, after purification, is improved by at least about 3%, about 5%, about 10%, about 12%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% compared to using wild-type T7 RNA polymerase.

[0032] In a sixth aspect, the present application provides a method for generating capped RNA by in vitro transcription, comprising incubating a DNA template with one or more RNA polymerase variants and cap analogs described in the present application in an in vitro transcription reaction system.

[0033] In some embodiments, the cap analog is a dinucleotide cap, a trinucleotide cap, or a tetranucleotide cap. In some embodiments, the cap analog is a trinucleotide cap. In some embodiments, the trinucleotide cap is selected from GAA, GAC, GAG, GAU, GCA, GCC, GCG, GCU, GGA, GGC, GGG, GGU, GUA, GUC, GUG, and GUU. In some embodiments, the trinucleotide cap is selected from m 7 GpppApA、m 7 GpppApC、m 7 GpppApG、m 7 GpppApU、m 7 GpppCpA、m 7 GpppCpC、m 7 GpppCpG、m 7 GpppCpU、m 7 GpppGpA、m 7 GpppGpC、m 7 GpppGpG、m 7 GpppGpU、m 7 GpppUpA、m 7 GpppUpC、m 7 GpppUpG, and m 7 In some embodiments, the trinucleotide cap is selected from m 7 G 3′OMe pppApA、m 7 G 3′OMe pppApC、m 7 G 3′OMe pppApG、m 7 G 3′OMe pppApU、m 7 G 3′OMe pppCpA、m 7 G 3′OMe pppCpC、m 7 G 3′OMe pppCpG、m 7 G 3′OMe pppCpU、m 7 G 3′OMe pppGpA、m 7 G 3′OMe pppGpC、m 7 G 3′OMe pppGpG、m 7 G 3′OMe pppGpU、m 7 G 3′OMe pppUpA、m 7 G3′OMe pppUpC、m 7 G 3′OMe pppUpG, and m 7 G 3′OMe In some embodiments, the trinucleotide cap is selected from m 7 G 3′OMe pppA 2′OMe pA, m 7 G 3′OMe pppA 2′OMe pC、m 7 G 3′OMe pppA 2′OMe pG、m 7 G 3′OMe pppA 2′OMe pU、m 7 G 3′OMe ppC 2′OMe pA, m 7 G 3′OMe ppC 2′OMe pC、m 7 G 3′OMe ppC 2′OMe pG、m 7 G 3′OMe ppC 2′OMe pU、m 7 G 3′OMe pppG 2′OMe pA, m 7 G 3′OMe pppG 2′OMe pC、m 7 G 3′OMe pppG 2′OMe pG、m 7 G 3′OMe pppG 2′OMe pU、m 7 G 3′OMe pppU 2′OMe pA, m 7 G 3′OMe pppU 2′OMe pC、m 7 G 3′OMe pppU 2′OMe pG, and m 7 G 3′OMe pppU 2′OMe In some embodiments, the trinucleotide cap is selected from m 7 GpppA 2′OMe pA, m 7 GpppA 2′OMe pC、m 7 GpppA 2′OMe pG、m7 GpppA 2′OMe pU、m 7 GpppC 2′OMe pA, m 7 GpppC 2′OMe pC、m 7 GpppC 2′OMe pG、m 7 GpppC 2′OMe pU、m 7 GpppG 2′OMe pA, m 7 GpppG 2′OMe pC、m 7 GpppG 2′OMe pG、m 7 GpppG 2′OMe pU、m 7 GpppU 2′OMe pA, m 7 GpppU 2′OMe pC、m 7 GpppU 2′OMe pG, and m 7 GpppU 2′OMe In some embodiments, the trinucleotide cap is preferably m7GpppA2′OMepG.

[0034] In some embodiments, when the polymerase variants described herein are used for in vitro transcription capping reactions, the capping efficiency of the mRNA product is increased to 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to that using wild-type T7 RNA polymerase (SEQ ID NO: 1). In some embodiments, the capping efficiency of the mRNA product can be increased to 100%.

[0035] In a seventh aspect, the present application provides a method for in vitro transcription, comprising contacting a DNA template with one or more RNA polymerase variants described herein under conditions that result in the production of an RNA transcription product, and incubating the mixture in an in vitro transcription system. In some embodiments, the method comprises the following steps: 1) providing a DNA template comprising a T7 promoter functionally linked to a target nucleotide sequence to be transcribed; 2) contacting the DNA template in step 1) with one or more RNA polymerase variants described herein; and 3) incubating the DNA template and RNA polymerase variant in an in vitro transcription system.

[0036] In some embodiments, the incubation temperature in step 3) is 30-50° C., preferably 37° C. In some embodiments, the incubation time in step 3) is 20-240 min, preferably 60 min.

[0037] The in vitro transcription system described in this application comprises nucleoside triphosphates and a buffer component.

[0038] In some embodiments, the nucleoside triphosphates can be selected from modified or unmodified nucleoside triphosphates (including analogs thereof). In some embodiments, the nucleoside triphosphates can be selected from unmodified ATP, GTP, CTP, UTP. In some embodiments, the nucleoside triphosphates can be selected from modified nucleoside triphosphates, including but not limited to m1A (N1-methyladenosine), m6A (N6-methyladenosine), m5C (5-methylcytidine), 5moU (5-methoxyuridine), ψ (pseudouridine), m1ψ (N1-methyl-pseudouridine), nucleoside triphosphates with labels (labels can be biotin, fluorescent substances, digoxin, radioactive elements, etc.).

[0039] In some embodiments, the in vitro transcription system further comprises an RNase inhibitor, an inorganic pyrophosphatase, and magnesium ions. In some embodiments, the in vitro transcription system further comprises DEPC water.

[0040] In an eighth aspect, the present application provides a composition or kit comprising one or more RNA polymerase variants described herein.

[0041] In one embodiment, the composition or kit further comprises one or more buffer components. In one embodiment, the composition or kit further comprises one or more in vitro transcription system components, wherein the in vitro transcription components can be selected from nucleoside triphosphates, RNase inhibitors, inorganic pyrophosphatase, magnesium ions, etc. In one embodiment, the in vitro transcription system components can be selected from commercially available mRNA in vitro transcription reagents.

[0042] In some embodiments, the composition or kit further comprises a cap analog. In some embodiments, the cap analog is a dinucleotide cap, a trinucleotide cap, or a tetranucleotide cap. In some embodiments, the cap analog is a trinucleotide cap. In some embodiments, the trinucleotide cap is selected from GAA, GAC, GAG, GAU, GCA, GCC, GCG, GCU, GGA, GGC, GGG, GGU, GUA, GUC, GUG, and GUU. In some embodiments, the trinucleotide cap is preferably m7GpppA2′OMepG.

[0043] In a ninth aspect, the present application provides a composition comprising RNA and a pharmaceutically acceptable excipient, wherein the RNA is produced by the in vitro transcription method described herein. In some embodiments, the RNA product is not chemically modified. In some embodiments, the RNA product is chemically modified.

[0044] Other implementation plans:

[0045] 1. An RNA polymerase variant, whose amino acid sequence comprises one, two, three, four or five amino acid mutations at positions selected from D130, N171, K172, R173, Y178, R298, Y385, K387, D388 or F880 relative to SEQ ID NO: 1, wherein the mutation type is substitution or deletion, and the amino acid sequence of the variant has a sequence identity of at least 97%, at least 98% or at least 99% to SEQ ID NO: 1.

[0046] 2. The variant as described in item 1, wherein the amino acid sequence of the variant has an amino acid mutation relative to SEQ ID NO: 1, and the position of the mutated amino acid is selected from N171, K172, R173, Y178, R298, Y385, K387, D388 or F880.

[0047] 3. The variant according to item 1, wherein the amino acid sequence of the variant relative to SEQ ID NO: 1 comprises:

[0048] (1) a mutation at position K172, and further comprising a mutation of any one, two, three or four amino acids selected from positions D130, R173, Y178, R298, Y385, K387, D388 or F880, wherein the mutation type is substitution or deletion; or

[0049] (2) a mutation at the K173 site, and further comprising a mutation of any one, two or three amino acids selected from the group consisting of D130, Y178, R298, K387 or D388, wherein the mutation type is a substitution or deletion; or

[0050] (3) Mutation of any two or three amino acids at positions R298, Y385, K387 or D388, where the mutation type is substitution.

[0051] 4. The variant as described in item 3, wherein the variant comprises a mutation group selected from any one of the following: K172+R173, D130+K172, K172+K387, K172+F880, K172+D388, K172+R298, D130+R173, R173+Y178, R173+D388, R173+R298, K387+R2 98. Y385+R298, D388+R298, Y385+K387, Y385+D388, K387+D388, K172+R173+Y385, K 172+R173+D388, K172+R173+K387, K172+R173+F880, K172+R173+Y178, D130+K172+ R173, D130+K172+Y178, D130+K172+K387, D130+R173+D388, K172+Y178+D388, D130 +K172+D388, K172+K387+R298, Y385+K387+D388, K172+R173+Y385+F880, K172+R17 3+D388+F880, K172+R173+Y178+D388, D130+K172+R173+D388, D130+K172+R173+Y178, D130+R173+Y178+K387, D130+K172+Y178+D388, or D130+K172+R173+Y178+D388.

[0052] 5. A variant as described in item 2, wherein

[0053] 1) The mutation type at position N171 is N171G;

[0054] 2) the mutation type at the K172 position is selected from DEL172, K172A, K172H, K172R, K172Y, K172S, K172E, K172D, K172W, K172F, K172I, K172M, K172V, K172P, K172T, K172C, K172N, K172Q, K172G or K172L;

[0055] 3) the mutation type at the R173 position is selected from DEL173, R173A, R173H, R173R, R173Y, R173S, R173E, R173D, R173W, R173F, R173I, R173M, R173V, R173P, R173T, R173C, R173N, R173Q, R173G or R173L;

[0056] 4) The mutation type at position Y178 is Y178H;

[0057] 5) The mutation type at position R298 is R298A;

[0058] 6) the mutation type at the Y385 position is selected from Y385A, Y385D or Y385E;

[0059] 7) the mutation type at the K387 position is selected from K387Q, K387Y, K387S or K387A;

[0060] 8) the mutation type at position D388 is selected from D388A, D388G or D388L; and

[0061] 9) The mutation type at position F880 is selected from F880A, F880G or F880W.

[0062] 6. The variant as described in item 3 or 4, wherein

[0063] 1) The mutation type at position D130 is D130E;

[0064] 2) The mutation type at the K172 position can be selected from DEL172, K172A or K172G;

[0065] 3) The mutation type at the R173 position can be selected from DEL173, R173A, R173G or R173C;

[0066] 4) The mutation type at position Y178 can be selected from Y178H or Y178P;

[0067] 5) The mutation type at position R298 is R298A;

[0068] 6) The mutation type at position Y385 is Y385A;

[0069] 7) The mutation type at the K387 position can be selected from K387S, K387Y or K387G;

[0070] 8) The mutation type at position D388 can be selected from D388Y, D388A or D388G; and

[0071] 9) The mutation type at position F880 can be selected from F880A or F880Y.

[0072] 7. The variant according to item 1, wherein the amino acid sequence of the variant is shown in any one of SEQ ID NOs: 2-141.

[0073] 8. A nucleotide sequence encoding the variant according to any one of items 1 to 7.

[0074] 9. A method for preparing an RNA polymerase variant, comprising producing at least one RNA polymerase variant as described in items 1-7 in a host cell; wherein the host cell contains an expression vector carrying the nucleotide sequence as described in item 8.

[0075] 10. A method for reducing the generation of dsRNA impurities during the in vitro transcription process for preparing RNA, comprising contacting a DNA template with a variant as described in any one of items 1 to 7, and incubating the mixture in an in vitro transcription system.

[0076] 11. A method for improving the integrity of in vitro transcribed RNA products, comprising contacting a DNA template with a variant as described in any one of items 1 to 7, and incubating the mixture in an in vitro transcription system.

[0077] 12. Use of at least one variant according to items 1 to 7 or the method according to items 10 to 11 for generating RNA by in vitro transcription.

[0078] 13. A method for generating RNA by in vitro transcription, comprising contacting a DNA template with at least one variant as described in items 1-7, and incubating the mixture in an in vitro transcription system.

[0079] 14. A method for generating capped RNA by in vitro transcription, comprising contacting a DNA template with at least one variant and a cap analog as described in items 1-7, and incubating the mixture in an in vitro transcription reaction system.

[0080] 15. A composition or kit comprising at least one RNA polymerase variant according to any one of items 1 to 7 and at least one buffer component.

[0081] 16. The composition or kit as described in item 15, further comprising a cap analog.

[0082] This application has the following beneficial effects:

[0083] The RNA polymerase variants of the present application have a high catalytic efficiency. When used in mRNA synthesis, they can reduce the production of double-stranded RNA contaminants. Compared with the existing reported mRNA preparation methods, the double-stranded RNA contaminants produced are the lowest, and it is a safe, green, and low-double-stranded RNA contaminant mRNA preparation method. The mRNA preparation method of the present application can greatly reduce the possibility of immunogenicity caused by double-stranded RNA impurities. In addition, some RNA polymerase variants provided in this application can improve the integrity of the in vitro transcribed product RNA; the variant DEL172+K387S can also improve the utilization rate of cap analogs in the co-transcription capping reaction, saving costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0084] Figure 1 is a schematic diagram of the construction of the recombinant plasmid. DETAILED DESCRIPTION

[0085] In the examples of the present application, enzyme activity is defined as the amount of enzyme required to generate 1 μmol of product or convert 1 μmol of substrate within 1 minute under specific reaction conditions.

[0086] Example 1 Preparation of RNA polymerase variants

[0087] The RNA polymerase and its variants shown in Table 1 were synthesized through DNA sequence (SEQ ID NO: 142-282) and PCR amplified. The DNA sequences were then introduced into the BseRI and HindIII restriction sites of the expression vector pQE-80L to obtain a recombinant expression vector. The constructed vector was introduced into E. coli BL21 (DE3) by chemical transformation technology, spread on an LB plate containing ampicillin resistance, and placed in a 37°C incubator overnight. The single colonies that grew were subjected to plasmid extraction and sequencing to obtain recombinant engineered bacteria containing the target gene. The successfully sequenced E. coli recombinant strain was inoculated into LB medium for overnight activation culture, and then 1-5% V / V was inoculated into the fermentation broth (LB medium) and cultured to an OD of 0. The 600 value was 0.6 to 0.8, IPTG was added at a final concentration of 0.5 mol / L and culture was continued for 4 to 6 hours. The strain was collected by centrifugation at 12000 rpm and 5°C, and the collected strain was washed with 0.2 M PBS buffer at a pH of 7.0 to obtain the bacteria. After ultrasonic disruption, affinity chromatography was performed to purify the RNA polymerase stock solution.

[0088] WT is a wild-type T7 RNA polymerase variant, whose amino acid sequence is:

[0089] RNA polymerase variants and their mutation sites are shown in Table 1:

[0090] Table 1: RNA polymerase variant mutation sites and corresponding amino acid sequence numbers

[0091] Example 2: dsRNA impurity generation during in vitro transcription

[0092] 2.1 Unmodified NTP

[0093] (1) The enzyme stock solution obtained in Example 1 was diluted with storage buffer (Vazyme, Catalog No.: DD4101) to an enzyme activity of 300 U / μL. The reaction components (20 μL) in Table 2 were added to the eight-well strips, mixed, and centrifuged; the eight-well strips were placed on a PCR instrument and reacted at 37°C for 1 hour, 36 μL of magnetic beads were added, mixed, and incubated at room temperature for 2-5 minutes; the mixture was placed on a magnetic rack to purify mRNA (Vazyme, Catalog No.: N412), and after purification, transferred to an RNase-free centrifuge tube to obtain purified mRNA;

[0094] (2) The dsRNA impurity content was tested using a dsRNA detection kit (Vazyme, catalog number: DD3509).

[0095] Table 2: Reaction system ratio

[0096] The dsRNA detection results are shown in Table 3. Compared with the WT group, most of the polymerase variants in Example 1 can effectively reduce the generation of dsRNA impurities during in vitro transcription. Among them, the variants in the DEL172-173+Y385A, DEL172-173+D388A, and DEL172-173+D388G groups can reduce the residual dsRNA amount by 99%.

[0097] Table 3: dsRNA residues

[0098] 2.2 Modified NTP (m1ψ)

[0099] (1) Dilute the enzyme stock solutions of RNA polymerase variants DEL172-173+Y385A, DEL172-173+D388A, and DEL172-173+D388G with storage buffer (Vazyme, Catalog No.: DD4101) to an enzyme activity of 300 U / μL. Add the reaction components (20 μL) listed in Table 4 to eight strips, mix well, and centrifuge. Place the eight strips on a PCR instrument and react at 37°C for 1 hour. Then add 36 μL of magnetic beads and mix well. Incubate at room temperature for 2-5 minutes. Place the mixture on a magnetic rack to purify mRNA (Vazyme, Catalog No.: N412). After purification, transfer to an RNase-free centrifuge tube to obtain purified mRNA.

[0100] (2) The dsRNA impurity content was tested using a dsRNA detection kit (Vazyme, catalog number: DD3509).

[0101] Table 4: Reaction system ratio

[0102] The dsRNA detection results showed that the in vitro transcription reaction involving the enzyme variants DEL172-173+D388A and DEL172-173+D388G could reduce the residual dsRNA rate (residual dsRNA amount / total RNA amount) to 0.0003%; the in vitro transcription reaction involving the enzyme variant DEL172-173+Y385A could reduce the residual dsRNA rate to 0.0001%.

[0103] Example 3 Comparison of the integrity of in vitro transcribed RNA products

[0104] 3.1 Unmodified NTP (template SEQ ID NO: 283)

[0105] (1) Purify the mRNA by referring to step (1) of 2.1 in Example 2;

[0106] (2) Capillary electrophoresis was performed using a Qsep400 fully automatic nucleic acid analyzer to detect the integrity of mRNA (intact RNA product / total RNA).

[0107] The test results are shown in Table 5-1 and Table 5-2.

[0108] 3.2 Modified NTP (m1ψ, template SEQ ID NO: 283)

[0109] (1) Purify the mRNA by referring to step (1) of 2.2 in Example 2;

[0110] (2) The integrity of mRNA was detected by capillary electrophoresis using a Qsep400 fully automatic nucleic acid analyzer.

[0111] The test results are shown in Table 5-1 and Table 5-2.

[0112] Table 5-1: Integrity of mRNA products

[0113] Table 5-2: Integrity of mRNA products

[0114] 3.3 saRNA Template I (Template SEQ ID NO: 284)

[0115] (1) Dilute the stock solution of RNA polymerase variant K387Y with storage buffer (Vazyme, Catalog No. DD4101) to an enzyme activity of 300 U / μL. Perform in vitro transcription according to the reaction system ratio in Table 2 to obtain purified mRNA;

[0116] (2) Capillary electrophoresis was performed using a Qsep400 fully automatic nucleic acid analyzer to detect the integrity of the saRNA product.

[0117] The test results showed that in the in vitro transcription reaction using wild-type T7 RNA polymerase (WT), the integrity of the transcription product was only 56.4%, while the use of the K387Y variant could increase the integrity of the saRNA product to 73.1%.

[0118] 3.4 saRNA Template II (>10000 nt)

[0119] (1) Dilute the stock solutions of RNA polymerase variants K387A and DEL172+K387Y with storage buffer (Vazyme, Catalog No. DD4101) to an enzyme activity of 300 U / μL. Perform in vitro transcription according to the reaction system ratios in Table 6 to obtain purified mRNA.

[0120] Table 6: Reaction system

[0121] (2) Capillary electrophoresis was performed using a Qsep400 fully automatic nucleic acid analyzer to detect the integrity of the saRNA product.

[0122] The test results showed that compared with the saRNA products obtained using the WT group polymerase, the variants of the K387A group and the DEL172+K387Y group could increase the integrity of the saRNA products by 3.1% and 4.9%, respectively.

[0123] Example 4 Preparation of capped RNA by in vitro transcription

[0124] (1) Dilute the stock solutions of K387Y and DEL172+K387S variant enzymes with storage buffer (Vazyme, catalog number: DD4101) to an enzyme activity of 300 U / μL. Prepare a MIX solution according to the reaction system (20 μL) in Table 7 and place it in an EP tube. Dispense the MIX solution into eight strips, mix well, and centrifuge. Place the eight strips in a PCR instrument and react at 37°C for 1 hour. Add 36 μL of magnetic beads, mix well, and incubate at room temperature for 2-5 minutes. Place the mixture on a magnetic rack to purify mRNA (Vazyme, catalog number: N412). After purification, transfer the mixture to an RNase-free centrifuge tube to obtain purified mRNA.

[0125] Table 7: Reaction system

[0126] (2) Capping rate detection:

[0127] ① Combine the purified mRNA obtained in step (1) with the probe. The reaction system is shown in Table 8, and the reaction conditions are shown in Table 9;

[0128] Table 8: Reaction system

[0129] Table 9: Reaction conditions

[0130] ②RNase H digestion: Prepare the enzyme digestion system (Thermo Scientific, Catalog No. EN0201) according to Table 10, vortex thoroughly to mix, and place in a PCR instrument for reaction at 25°C for 20 min.

[0131] Table 10: Reaction system

[0132] ③SA magnetic bead binding:

[0133] A. Magnetic Bead Wash: Transfer 9 μL of SA magnetic beads to a centrifuge tube and place on a magnetic rack. Once the solution becomes clear, aspirate and discard the supernatant. Remove the tube from the magnetic rack and rinse with 200 μL of RNase-free H2O. Place the tube on a magnetic rack. Once the solution becomes clear, aspirate and discard the supernatant. Repeat the rinse with 200 μL of RNase-free H2O.

[0134] B. Reaction conditions: Remove the centrifuge tube from the magnetic rack, add the enzyme digestion product to the SA magnetic beads, pipette up and down 20-30 times to mix thoroughly, and place on a roller to incubate at room temperature for 30 minutes to allow the magnetic beads and enzyme digestion product to fully bind.

[0135] ④ Rinse and wash:

[0136] A. Place the product from step ③ on a magnetic rack for 2-3 minutes until the solution becomes clear. Use a pipette to discard the supernatant.

[0137] B. Add 200 μL of rinse buffer, taking care not to disperse the magnetic beads, let it stand for 0.5 to 1 minute, and discard the supernatant with a pipette;

[0138] C. Repeat step B;

[0139] D. Remove the centrifuge tube from the magnetic stand, add 30uL of elution buffer, and pipette 10-20 times to mix evenly to evenly disperse the magnetic beads and fully elute them;

[0140] E. Place the tube in a PCR instrument and react at 85°C for 3 minutes. Immediately place the tube on a magnetic rack. Once the solution has clarified (0.5-1 minute), transfer the supernatant to a new centrifuge tube. The supernatant is the desired product.

[0141] F. Use capillary electrophoresis to detect the capping rate of the product in step E. The capping rate is calculated by the formula:

[0142] Cap1 capping rate % = [Cap1 peak area / (Uncap peak area + Cap1 peak area)] × 100%.

[0143] The test results showed that in the co-transcriptional capping reaction, the capping rate of mRNA products in the WT (wild-type T7 RNA polymerase) group was only 87.2%, while the variants in the K387Y group could increase the capping rate of mRNA products to 91.3%, and the variants in the DEL172+K387S group could increase it to 100%.

Claims

1. A variant of an RNA polymerase, the amino acid sequence of which comprises, relative to SEQ ID NO: 1, one, two, three, four or five amino acid mutations at positions selected from D130, N171, K172, R173, Y178, R298, Y385, K387, D388 or F880, wherein: The mutation type is substitution or deletion, and the amino acid sequence of the variant has a sequence identity of at least 97%, at least 98% or at least 99% to SEQ ID NO:

1.

2. A variant according to claim 1, wherein The amino acid sequence of the variant has an amino acid mutation relative to SEQ ID NO: 1, and the position of the mutated amino acid is selected from N171, K172, R173, Y178, R298, Y385, K387, D388 or F880.

3. A variant according to claim 1, wherein The amino acid sequence of the variant relative to SEQ ID NO: 1 comprises: (1) a mutation at position K172, and further comprising a mutation of any one, two, three or four amino acids selected from positions D130, R173, Y178, R298, Y385, K387, D388 or F880, wherein the mutation type is substitution or deletion; or (2) a mutation at the K173 site, and further comprising a mutation of any one, two or three amino acids selected from the group consisting of D130, Y178, R298, K387 or D388, wherein the mutation type is a substitution or deletion; or (3) Mutation of any two or three amino acids at positions R298, Y385, K387 or D388, where the mutation type is substitution.

4. A variant as claimed in claim 3, wherein The variant comprises a mutation group selected from any one of the following: K172+R173, D130+K172, K172+K387, K172+F880, K172+D388, K172+R298, D130+R173, R173+Y178, R173+D388, R173+R298, K387+R298, Y385+R2 98. D388+R298, Y385+K387, Y385+D388, K387+D388, K172+R173+Y385, K172+R173 +D388、K172+R173+K387、K172+R173+F880、K172+R173+Y178、D130+K172+R173、D1 30+K172+Y178, D130+K172+K387, D130+R173+D388, K172+Y178+D388, D130+K172 +D388、K172+K387+R298、Y385+K387+D388、K172+R173+Y385+F880、K172+R173+D 388+F880, K172+R173+Y178+D388, D130+K172+R173+D388, D130+K172+R173+Y178, D130+R173+Y178+K387, D130+K172+Y178+D388, or D130+K172+R173+Y178+D388.

5. A variant as claimed in claim 2, wherein 1) The mutation type at position N171 is N171G; 2) the mutation type at the K172 position is selected from DEL172, K172A, K172G, K172E, K172D, K172H, K172Y, K172S, K172W, K172P, K172I, K172M, K172V, K172F, K172T, K172C, K172N or K172L; 3) the mutation type at the R173 position is selected from DEL173, R173A, R173C, R173G, R173E, R173D, R173H, R173Y, R173S, R173W, R173P, R173N or R173Q; 4) The mutation type at position Y178 is Y178H; 5) The mutation type at position R298 is R298A; 6) the mutation type at the Y385 position is selected from Y385A, Y385D or Y385E; 7) the mutation type at the K387 position is selected from K387Q, K387Y, K387S or K387A; 8) the mutation type at position D388 is selected from D388A, D388G or D388L; and 9) The mutation type at the F880 position is selected from F880A, F880G or F880W.

6. A variant as claimed in claim 3 or 4, wherein 1) The mutation type at position D130 is D130E; 2) The mutation type at the K172 position can be selected from DEL172, K172A or K172G; 3) The mutation type at the R173 position can be selected from DEL173, R173A, R173G or R173C; 4) The mutation type at position Y178 can be selected from Y178H or Y178P; 5) The mutation type at position R298 is R298A; 6) The mutation type at position Y385 is Y385A; 7) The mutation type at the K387 position can be selected from K387S, K387Y or K387G; 8) The mutation type at position D388 can be selected from D388Y, D388A or D388G; as well as 9) The mutation type at position F880 can be selected from F880A or F880Y.

7. The variant of claim 1, wherein The amino acid sequence of the variant is shown in any one of SEQ ID NOs: 2-141.

8. A nucleotide sequence encoding the variant according to any one of claims 1 to 7.

9. A method for preparing an RNA polymerase variant, comprising producing at least one RNA polymerase variant according to claims 1 to 7 in a host cell; wherein, The host cell contains an expression vector carrying the nucleotide sequence as claimed in claim 8.

10. A method for reducing the generation of dsRNA impurities during the preparation of RNA by in vitro transcription, comprising contacting a DNA template with a variant according to any one of claims 1 to 7, and incubating the mixture in an in vitro transcription system.

11. Use of at least one variant according to claim 1 to 7 or the method according to claim 10 for producing RNA by in vitro transcription.

12. A method for generating RNA by in vitro transcription, comprising contacting a DNA template with at least one variant according to claims 1 to 7, and incubating the mixture in an in vitro transcription system.

13. A method for generating capped RNA by in vitro transcription, comprising contacting a DNA template with at least one variant according to claims 1 to 7 and a cap analog, and incubating the mixture in an in vitro transcription reaction system.

14. A composition or kit comprising at least one RNA polymerase variant according to any one of claims 1 to 7 and at least one buffer component.

Citation Information

Patent Citations

  • RNA polymerase variants for co-transcriptional capping

    CN113795579A

  • T7-RNA polymerase mutant suitable for synthesizing RNA in vitro and application of T7-RNA polymerase mutant

    CN115975974A

  • Mutant rna polymerases

    US20040259089A1

  • Methods and materials for reducing production of aberrant products during rna synthesis

    US20060063154A1

  • Highly Productive One-Pot System for the Incorporation of Non-Standard Amino Acids into Cell-Free Synthesized Proteins

    US20180016614A1

Cited By

  • T7 RNA polymerase mutant and application thereof

    CN119464247A

  • A T7 RNA polymerase mutant and its application

    CN119464247B

  • RNA polymerase variants and uses thereof

    CN121294389A

  • RNA polymerase variants and uses thereof

    CN121555463A

  • RNA polymerase variants and uses thereof

    CN121555463B